【导读】这项研究评估了鞘内培美曲塞（IP）对既往接受过治疗的表皮生长因子受体（EGFR）突变晚期非小细胞肺癌（NSCLC）患者脑膜转移瘤（LM）的治疗效果。2024年12月7日，中南大学湘雅医学院附属肿瘤医院张永昌教授团队在期刊《Heliyon》上发 ...

In the conclusion to our interview with Joshua K. Sabari, MD, which focused on the first-line approval of amivantamab (Ami; ...

Stanford University medical professor Dr. Bryant Lin was diagnosed with stage IV lung cancer despite never smoking. Now, he's ...

A mutation in the gene that codes for the epidermal growth factor receptor, or EGFR, has been associated with an increased risk of lung cancer. It is just one of several genetic mutations that are ...

默沙东（MSD）公司今日宣布，美国FDA已授予在研抗体偶联药物（ADC）sacituzumab ...

AstraZeneca and Daiichi Sankyo have shared the data they believe can secure approval for datopotamab deruxtecan (Dato-DXd) at ...

The FDA has granted Breakthrough Therapy Designation to datopotamab deruxtecan (Dato-DXd) for advanced EGFR-mutated non-small cell lung cancer.

Greater ORR of 55.6% was seen in patients with EGFR sensitizing and T790M double mutations (78% had received third-generation EGFR-TKI treatment in prior lines of therapy). Sunvozertinib was ...

The FDA granted breakthrough therapy status to sacituzumab tirumotecan in EGFR-mutated advanced non–small cell lung cancer.

Dizal announces positive pooled data of sunvozertinib in EGFR TKI-resistant NSCLC: Shanghai, China Friday, December 13, 2024, 18:00 Hrs [IST] Dizal, a biopharmaceutical company co ...

The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan (sac-TMT) for advanced NSCLC with EGFR ...

Merck & Co., Inc. (MRK) announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...